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Edited by Francesc PosasAbstract NDRG1 is phosphorylated by SGK1 (but not PKB) in
vivo at three residues each contained within three nonapeptide re-
peats. Here, we demonstrate that this nonapeptide, like the
NDRG1 protein, is phosphorylated by SGK1, but not by PKBa
or RSK1 in vitro. The inability of PKBa and RSK1 to phosphor-
ylate the nonapeptide was traced to residues n + 1, n + 2 and
n  4 (where n is the phosphorylation site). Changing them from
Ser, Glu and Ser to Phe, Ala and Pro, respectively, transformed
the nonapeptide into an excellent substrate for PKBa and RSK1.
Our results identify a speciﬁc substrate for SGK1 and may facil-
itate detection of additional physiological substrates for this
enzyme.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ‘‘AGC’’ subfamily of protein kinases comprises enzymes
that play key roles in signal transduction by extracellular agon-
ists. They include cyclic AMP and cyclic GMP-dependent pro-
tein kinases, the diacyl-glycerol-activated isoforms of protein
kinase C, ribosomal S6 kinases (RSKs, S6Ks) and mitogen
and stress-activated protein kinases (MSKs) that are compo-
nents of MAP kinase cascades, as well as protein kinase B
(PKB/Akt) and serum and glucocorticoid-induced protein ki-
nases (SGKs) that are activated by insulin and other signals
that switch on phosphatidylinositol 3-kinase.
Nearly all AGC family members phosphorylate serine and/
or threonine residues that lie C-terminal to clusters of basic
amino acid residues that are critical for their speciﬁcity. For
example, several AGC family members, such as PKB, SGK,
RSK and S6K, preferentially phosphorylate Arg–Xaa–Arg–
Xaa–Xaa–Ser/Thr motifs [1]. This allows these protein kinases
to target the same amino acid residues in such proteins, allow-
ing these substrates to respond to several physiological stimuli.
For example, the protein kinase glycogen synthase kinase 3Abbreviations: GST, glutathione S-transferase; GSK3, glycogen syn-
thase kinase 3; PKB, protein kinase B; RSK, p90 ribosomal S6 kinase;
S6K, p70 S6 kinase; SGK, serum and glucocorticoid-induced kinase
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by RSK in response to growth factors [3] or by S6K in re-
sponse to amino acids [4]. Similarly, the Tuberous Sclerosis
Complex (TSC) can be phosphorylated by PKB or RSK in
cells, preventing it from inhibiting activation of the mamma-
lian target of rapamycin (mTOR) [5,6].
However, it is also obvious that each of these protein ki-
nases phosphorylate speciﬁc targets. This is evident, for
example, from the phenotypes of mice that do not express
these enzymes. Thus mice that do not express the b-isoform
of PKB are deﬁcient in insulin-stimulated glucose uptake into
muscle and become diabetic as they age [7], whilst SGK1-
deﬁcient mice are unable to excrete sodium ions normally
from the kidney, due to defects in the regulation of several
ion channels [8].
We have developed a method called KESTREL (kinase sub-
strate tracking and elucidation) for identifying the physiologi-
cal substrates of protein kinases, and have recently exploited it
to identify proteins in cell extracts that are phosphorylated by
PKB, but not by SGK ([9] and R. Cartlidge, G. Auld and P.
Cohen, unpublished work), with which it shares 54% sequence
identity in its catalytic domain. Conversely, we have also de-
tected proteins that are phosphorylated by SGK1, but not by
PKBa, and identiﬁed them as the protein products of the N-
myc downstream regulated gene NDRG1 and its homologue
NDRG2 [10]. These proteins are phosphorylated in vivo at
the sites targeted by SGK1 in vitro, but not in mice that do
not express SGK1 or in cells where SGK1 has been ‘‘knocked
down’’ using speciﬁc siRNAs. This and other evidence indi-
cates that NDRG1 and NDRG2 are indeed physiological sub-
strates of SGK1, and that PKB isoforms are unable to
substitute for SGK1, even when the latter is not expressed.
This is surprising since the major sites on NDRG1 and
NDRG2 that are phosphorylated by SGK1 are located in
canonical Arg–Xaa–Arg–Xaa–Xaa–Ser/Thr sequences.
Three of the sites in NDRG1 that are targeted by SGK1 lie
in a nonapeptide sequence, Arg–Ser–Arg–Ser–His–Thr–Ser–
Glu–Gly, that is repeated three times near the C-terminus of
the protein [10]. In this paper, we synthesised this nonapeptide
and found that, similar to the NDRG1 protein [10], it is phos-
phorylated eﬃciently by SGK1, but extremely poorly by
PKBa, RSK1 and S6K1 in vitro. Thus, the speciﬁc phosphor-
ylation of NDRG1 by SGK1 in vitro can be recapitulated
using the nonapeptide. By making a number of variants of this
peptide, we have been able to identify the residues that prevent
phosphorylation by PKBa and RSK1. This has provided new
insights into the molecular basis for the distinct speciﬁcities ofblished by Elsevier B.V. All rights reserved.
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other proteins that are physiological substrates for SGK.Fig. 1. Relative rates of phosphorylation of RSRSHTSEG (MUR-
RAYtide) and RPRSHTFAG by PKBa, SGK1, RSK1 and S6K1.
Peptides were phosphorylated at 30 C for 7.5 min with 1.0 U/ml of
PKBa (n), or SGK1 (m), RSK1 (n), and S6K1 (h), which had been
matched for activity against 30 lM CROSStide.2. Materials and methods
2.1. Materials
[c-32P]ATP and materials for protein puriﬁcation were obtained
from Amersham Biosciences (Chalfont St Giles, UK). All other chem-
icals were of the highest purity and purchased from Merck (Poole,
UK) or Sigma–Aldrich (Poole, UK).
2.2. Protein expression and puriﬁcation
All His-tagged proteins were expressed in insect Sf21 cells. His-
tagged PKBa [118–480] in which Ser473 was mutated to Asp, SGK1
[60–431] in which Ser422 was mutated to Asp and S6K1 [1–421] in
which Thr412 was mutated to Glu were puriﬁed by chromatography
on nickel-nitrilotriacetate (Ni-NTA) agarose and then maximally acti-
vated by phosphorylation with His-tagged PDK1 [52–556]. N-termi-
nally his-tagged full length RSK1 [1–735] was puriﬁed and then
maximally activated with PDK1 and full length glutathione S-transfer-
ase (GST)-ERK2. The PDK1 bound very tightly to heparin-Sepharose
[11] and was removed from all activated protein kinases by passage
through this column. GST-ERK2 was removed by passage through
glutathione agarose. The activated protein kinases were concentrated
by repuriﬁcation on Ni-NTA-agarose, dialysed against 50 mM Tris/
HCl, pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1 mM EGTA, 0.1%
(v/v) 2-mercaptoethanol, 0.2 mM phenylmethylsulphonyl ﬂuoride
and 1 mM benzamidine and stored at 80 C.
2.3. Synthesis of peptides
The peptide termed Sgktide (KKRNRTLSVA) was synthesised on
an Applied Biosystems 431A peptide synthesiser [12] and all other pep-
tides were synthesised using Fmoc chemistry [13] on an Applied Bio-
systems 9050+ or Pioneer automatic peptide synthesiser. Peptides
were puriﬁed by reverse-phase HPLC on a C18 silica wide-pore column
(15 cm · 2.1 mm) with an elution gradient of 10–50% acetonitrile con-
taining 0.1% (v/v) triﬂuoroacetic acid over 40 min. Further puriﬁca-
tion, where necessary, was performed on a 25 cm · 22 mm column
using the same conditions. The molecular mass was conﬁrmed by mass
spectrometry performed on a VG Quattro triple-quadrupole instru-
ment with electrospray ionisation. Peptide synthesis reagents were pur-
chased from Bachem (St. Helens, UK) or Calbiochem (Nottingham,
UK).
2.4. Assay of protein kinases
These were assayed at 30 C as described previously [14,15]. One
Unit of PKBa, SGK1, RSK1 and S6K1 was that amount which catal-
ysed the phosphorylation of 1 nmol of the standard substrate peptide
CROSStide (GRPRTSSFAEG) in 1 min [2]. Each peptide substrate
was used at the concentrations indicated in Section 3 and incubated
for 7.5 min in 25 ll reaction volumes at 30 C with 10 mM MgCl2–
0.1 mM [c-32P]ATP (106 cpm/nmol) in 50 mM Tris/HCl, pH 7.5, con-
taining 0.05% (v/v) 2-mercaptoethanol and 1.0 U/ml of recombinantTable 1
Relative eﬀectiveness of diﬀerent peptides as substrates for PKBa, SGK1 an
Peptide PKB SG
Vmax (U/mg) Km (lM) Vm
1 GRPRTSSFAEG 1160 23 61
2 RSRSHTSEG ND >1000 11
3 RSRSHTFEG 1210 270 12
4 RSRSLTSEG ND >1000 94
5 RSRSHTSAG 1190 440 13
6 RSRSHTFAG 1700 43 13
7 RPRSHTSEG 354 220 14
8 RPRSHTFEG 1410 110 10
9 RPRSHTFAG 1720 26 12
The phosphorylated residue is shown in boldface type and the substituted reprotein kinase. Incorporation of phosphate was linear with respect
to time under the conditions used. Reactions were terminated by spot-
ting on to phosphocellulose paper, followed by immersion in 75 mM
phosphoric acid. All papers were then washed four times in 75 mM
phosphoric acid to remove unincorporated ATP, once in acetone
and then dried and 32P incorporation was determined by Cerenkov
counting.3. Results and discussion
The peptide substrate that is used to assay PKB routinely,
Arg–Pro–Arg–Thr–Ser–Ser–Phe–Ala–Glu–Gly (CROSStide),
is similar to the sequence surrounding the residue in GSK3
that is phosphorylated by PKB in vitro and in cells. The sec-
ond serine in the peptide sequence is the site of phosphoryla-
tion and conforms to the canonical sequence motif for
phosphorylation by PKB or SGK [2]. This peptide was phos-
phorylated by PKB and SGK with Km values of 23 and
5 lM respectively, and Vmax/Km values that were also similar
(Table 1, peptide 1). In contrast the nonapeptide Arg–Ser–
Arg–Ser–His–Thr–Ser–Glu–Gly, which is repeated three times
near the C-terminus of NDRG1, was barely phosphorylated
by PKBa, RSK1 or S6K1. The Km values were far higher than
1 mM (Fig. 1A) and the Vmax for each kinase could not there-
fore be determined (Table 1, peptide 2, and data not shown).
Nevertheless SGK1 phosphorylated the peptide with a Km of
72 lM and with a Vmax that was nearly twofold higher than
CROSStide (Fig. 1A, and Table 1, peptide 2). The nonapeptide
is therefore a rather speciﬁc substrate for SGK1 and is hereaf-
ter termed MURRAYtide.d RSK1
K RSK1
ax (U/mg) Km (lM) Vmax (U/mg) Km (lM)
6 5 1492 7
60 72 ND >1000
80 16 573 133
0 100 ND >1000
00 26 ND >1000
70 14 1237 50
00 40 824 418
70 10 1102 114
90 13 1933 81
sidues are underlined. ND, not determined.
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poor substrate for PKBa, we synthesised further peptides
in which one or more residues were substituted by other
amino acids. Previous studies with synthetic peptide sub-
strates have revealed that PKBa has a strong preference
for a bulky hydrophobic residue at the position immediately
C-terminal to the site of phosphorylation, termed n + 1
where n is the site of phosphorylation [1]. Since this residue
is serine in MURRAYtide, we initially changed it to phen-
ylalanine. This substitution did indeed improve the ability
of PKBa and RSK1 to phosphorylate the peptide (Table
1, peptide 3), but the Km for each kinase was still at least
10-fold higher than CROSStide. Moreover, this mutation
also decreased by 4–5-fold the Km for phosphorylation by
SGK1 (Table 1, peptide 3), so that the peptide was still
phosphorylated far more eﬃciently by SGK1 than PKBa
or RSK1.
None of the known physiological substrates for PKB con-
tain a histidine residue immediately N-terminal to the site
of phosphorylation (n  1), and we therefore wondered
whether its presence in MURRAYtide might be deleterious
to phosphorylation by PKBa. However, its replacement by
leucine, which is reported in one study to be favoured by
PKB [16], did not improve the ability of MURRAYtide
to be phosphorylated by PKBa or RSK1 (Table 1,
peptide 4).
We next considered the possibility that the presence of an
acidic residue at position n + 2 might be deleterious for protein
kinases other than SGK1 (the glutamate residue in CROSStide
is at n + 3). The substitution of the glutamate at n + 2 by ala-
nine did indeed improve the ability of MURRAYtide to be
phosphorylated by PKBa, and it also reduced the Km for phos-
phorylation by SGK1 2–3-fold (Table 1, peptide 5). Thus, an
acidic residue at this position is a negative determinant for
SGK1 and PKBa. The glutamate to alanine mutation did
not improve the peptide as a substrate for RSK1. However,
replacing both the serine at n + 1 with phenylalanine and the
glutamate at n + 2 with alanine greatly improved the ability
of MURRAYtide to be phosphorylated by PKBa and
RSK1, and this peptide was now phosphorylated by both pro-
tein kinases with a Km value only 2–7-fold higher than
CROSStide and with a similar Vmax (Table 1, peptide 6). Nev-
ertheless, the peptide RSRSHTFAG was still phosphorylated
by SGK1 with a threefold lower Km than PKBa, and we there-
fore looked for another residue(s) that might account for this
diﬀerence.
A number of the physiological substrates for PKB, including
FOXO1a (formerly FKHR) [17], GSK3b [2] and PDE-3B [18],
possess a proline residue at n  4 between the two arginine res-
idues at n  3 and n  5 that are critical for the speciﬁcity of
this protein kinase, whereas this residue is serine in MUR-
RAYtide/NDRG1 (Table 1, peptide 2). In the case of
NDRG1, the presence of serine at this position is critical, since
one role for SGK1 phosphorylation is to prime NDRG1 for
phosphorylation by GSK3, which phosphorylates serine/threo-
nine residues located 4-residues N-terminal to another phos-
phorylated serine/threonine residue [19]. Mutation of the
serine at n  4 to proline did indeed improve the ability of
MURRAYtide to be phosphorylated by PKBa and RSK1.
However, for PKBa, the eﬀect was not as marked as the muta-
tion of glutamate to alanine at n + 2 (Table 1, peptides 5
and 7).After mutating all three residues, i.e. the serine at n  4 to
proline, the serine at n + 1 to phenylalanine and the glutamate
at n + 2 to alanine (Fig. 1B), the resulting peptide was phos-
phorylated by PKBa and RSK1 at least as eﬃciently as
CROSStide (compare peptides 1 and 9 in Table 1) and with
comparable kinetics to SGK1. It should be noted that after
the combined mutation of these three residues, S6K1 was still
unable to phosphorylate the peptide. The reason for this is un-
known.
In summary, this study has introduced a speciﬁc peptide sub-
strate for the assay of SGK1 and is likely to explain why
NDRG1 is phosphorylated in vitro and in vivo by SGK1
but not by PKBa. The molecular basis for this discrimination
arises from the presence of three residues within the nonapep-
tide repeat sequence that are negative determinants for phos-
phorylation by PKBa and RSK1, and which, in
combination, essentially prevent the phosphorylation of
NDRG1 by protein kinases other than SGK1.
Arg–Xaa–Arg–Xaa–Xaa–Ser/Thr motifs are present in
many proteins. Clearly, such motifs must be located on ex-
posed regions on the surface of proteins in order to be
accessible to protein kinases and therefore not all such mo-
tifs will be phosphorylated in cells. However, the present re-
sults, in conjunction with an earlier report [20], indicates
that SGK can tolerate more variation in the other amino
acids surrounding this motif. One might therefore predict
that SGK is likely to phosphorylate many more of these
motifs in cells. This would be consistent with SGK being
an immediate early gene whose synthesis increases dramati-
cally within an hour of exposing cells to a diverse array of
extracellular signals that include serum, glucocorticoids, min-
eralocorticoids, cellular stresses and growth factors, reviewed
in [21].
In the light of our results, it may be possible to predict
candidate substrates for phosphorylation by SGK, but not
PKB. However, caution must be exercised in extrapolating
from synthetic peptides to native protein substrates, where
particular features of the three-dimensional structure or
the presence of ‘‘docking sites’’ for particular protein ki-
nases may sometimes modify or override the need for a
‘‘normal’’ recognition motif. For example, one of the phos-
phorylation sites (Ser319) in the transcription factor FOX-
O1a is followed by a serine, but is clearly phosphorylated
by PKB and not by SGK in IGF-1 stimulated embryonic
stem cells [22]. Similarly, although MAP kinases nearly al-
ways phosphorylate serine or threonine residues that are
followed by proline, there are clearly a few physiological
substrates where this ‘‘dogma’’ does not apply [23]. Never-
theless, information obtained with synthetic peptides is gen-
erally a useful guide and we anticipate that the present
study will stimulate the identiﬁcation of more substrates
for SGK1 in the future.
A peptide called Sgktide (KKRNRRLSVA), has been used
to assay SGK1 in vitro [24]. However, this is a misnomer be-
cause, in our assays, Sgktide is phosphorylated by PKBa and
SGK1, with similar Vmax (1540 and 1330 U/mg, respectively)
and Km values (100 and 20 lM, respectively). It is also phos-
phorylated by RSK1 with a Vmax nearly twofold higher than
CROSStide (data not shown). The identiﬁcation of MUR-
RAYtide as an SGK1-speciﬁc peptide substrate may lead to
the adoption of this peptide as the standard substrate for the
assay of SGK1 activity.
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